In a recent post on the IVI-sponsored Health Affairs featured blog series, Robert Bohrer addresses the current system in place for the accelerated approval of novel drugs and notes the delicate issues that regulators are confronted with. Bohrer suggests that a new “conditional approval” approach may be the best compromise and provide a way forward.

Read the full article here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.